Open AccessHMQ‐T‐F2 exert antitumour effects by upregulation of Axin in human cervical HeLa cells
Author(s) -
Dai Bingling,
Yang Tianfeng,
Ma Yujiao,
Ma Nan,
Shi Xianpeng,
Zhang Dongdong,
Zhang Jie,
Zhang Yanmin
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13577
Subject(s) - hela , wnt signaling pathway , cell growth , downregulation and upregulation , cancer research , microbiology and biotechnology , catenin , chemistry , cell , biology , signal transduction , biochemistry , gene
Looking for novel, effective and less toxic therapies for cervical cancer is of significant importance. In this study, we reported that HMQ‐T‐F2(F2) significantly inhibited cell proliferation and transplantable tumour growth. Mechanistically, HMQ‐T‐F2 inhibited HeLa cell growth through repressing the expression and nuclear translocation of β‐catenin, enhancing Axin expression, as well as downregulating the Wnt downstream targeted proteins. Knock‐down of a checkpoint β‐catenin by si RNA significantly attenuated HeLa cell proliferation. Furthermore, XAV 939, an inhibitor of β‐catenin, was used to treat HeLa cells and the results demonstrated that HMQ‐T‐F2 inhibited proliferation and migration via the inhibition of the Wnt/β‐catenin pathway.